Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

News
The deadline for the annual report 2015 is January 31st, 2016

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-48867

von Boehmer, Lotta; Keller, Lukas; Mortezavi, Ashkan; Provenzano, Maurizio; Sais, Giovanni; Hermanns, Thomas; Sulser, Tullio; Jungbluth, Achim A; Old, Lloyd J; Kristiansen, Glen; van den Broek, Maries; Moch, Holger; Knuth, Alexander; Wild, Peter J (2011). MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE, 6(7):e21366.

[img]
Preview
Published Version
Creative Commons: Attribution 3.0 Unported (CC BY 3.0)
PDF
1MB
View at publisher

Abstract

The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms. In most cases, no CT antigen is found in normal tissues, except in testis, making them ideal targets for cancer immunotherapy. A comprehensive analysis of CT antigen expression has not yet been reported in prostate cancer. MAGE-C2/CT-10 is a novel CT antigen. The objective of this study was to analyze extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer. 348 prostate carcinomas from consecutive radical prostatectomies, 29 castration-refractory prostate cancer, 46 metastases, and 45 benign hyperplasias were immunohistochemically analyzed for MAGE-C2/CT10 expression using tissue microarrays. Nuclear MAGE-C2/CT10 expression was identified in only 3.3% primary prostate carcinomas. MAGE-C2/CT10 protein expression was significantly more frequent in metastatic (16.3% positivity) and castration-resistant prostate cancer (17% positivity; p<0.001). Nuclear MAGE-C2/CT10 expression was identified as predictor of biochemical recurrence after radical prostatectomy (p = 0.015), which was independent of preoperative PSA, Gleason score, tumor stage, and surgical margin status in multivariate analysis (p<0.05). MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. Further, the results suggest MAGE-C2/CT10 as a potential target for adjuvant and palliative immunotherapy in patients with prostate cancer.

Citations

13 citations in Web of Science®
14 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

95 downloads since deposited on 02 Aug 2011
16 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > University Hospital Zurich > Urological Clinic
04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2011
Deposited On:02 Aug 2011 11:24
Last Modified:02 Dec 2015 07:49
Publisher:Public Library of Science (PLoS)
ISSN:1932-6203
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.1371/journal.pone.0021366
PubMed ID:21754986

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page